47. (New) The particle of claim 44, wherein said particle forms an amphipathic compound.

48. (New) The particle of claim 45, wherein said polar lipid comprises from 0 to 50 percent by weight of said particle.

49. (New) The particle of claim 45, wherein said polar lipid comprises from 10 to 50 percent by weight of said particle.

50. (New) The particle of claim 45, wherein said polar lipid comprises from 15 to 55 percent by weight of said particle.

51. (New) The particle of claim 45, wherein said polar lipid comprises from 1 to 30 percent by weight of said particle.

52. (New) The particle of claim 45, wherein said neutral lipid comprises from 0 to 90 percent by weight of said particle.

53. (New) The particle of claim 45, wherein said neutral lipid comprises from 0 to 10 percent by weight of said particle.

54. (New) The particle of claim 45, wherein said neutral lipid comprises from 30 to 90 percent by weight of said particle.

55. (New) The particle of claim 45, wherein said neutral lipid comprises from 2 to 30 percent by weight of said particle.

56. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 0.5 to 90 percent by weight of said particle.

57. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 50 to 90 percent by weight of said particle.

58. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 30 to 80 percent by weight of said particle.

59. (New) The particle of claim 44, wherein said truncated apolipoprotein B protein comprises from 0.5 to 10 percent by weight of said particle.

60. (New) The particle of claim 46, wherein said formed lipophilic compound is from 0.1 to 90 percent by weight of the particle.

61. (New) The particle of claim 47, wherein said formed amphipathic compound is from 0.1 to 90 percent by weight of the particle.

62. (New) The particle according to claim 44, wherein said apolipoprotein B further comprises a fused heterologous moiety, where said heterologous moiety is a member of a specific binding pair.

63. (New) The particle according to claim 53, wherein said heterologous moiety is a peptide.

64. (New) The particle according to claim 53, wherein said heterologous moiety is an antibody.

65. (New) The particle according to claim 53, wherein said heterologous moiety is a single chain antibody.

66. (New) The particle according to claim 53, wherein said heterologous moiety is a single chain anti HER2 antibody.

67. (New) The particle according to claim 44, wherein said particle has a diameter of less than 18 nanometers.

68. (New) The particle according to claim 44, wherein said particle has a diameter of from 5 to 5,000 nanometers.

69. (New) The particle according to claim 44, wherein said apolipoprotein B protein is selected from the group consisting of apoB6 through apoB74.

70. (New) The particle according to claim 44, wherein said particle has a neutral core, and wherein said apolipoprotein B protein comprises at least ApoB 19.5.

71. (New) The particle according to claim 44, wherein said apolipoprotein B protein is mature Apo B.

72. (New) The particle according to claim 44, wherein said apolipoprotein B protein is mammalian Apo B.

73. (New) The particle according to claim 44, wherein said apolipoprotein B protein is human Apo B.

74. (New) The particle according to claim 45, wherein said at least one polar lipid is a phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, glycosphingolipid, lysolipid thereof, or combinations thereof.

75. (New) The particle according to claim 45, wherein said at least one neutral lipid comprises a triglyceride, cholesterol, derivative thereof, or combinations thereof.

76. (New) The particle according to claim 44, wherein said compound delivery particle is paclitaxel.

77. (New) The particle according to claim 44, wherein said particle is a small emulsion particle.

78. (New) The particle according to claim 44, wherein said particle is a large emulsion particle.

79. (New) The particle according to claim 44, wherein said compound to be delivered is an amphipathic compound, and wherein said amphipathic compound comprises a synthetic lipid.

80. (New) A pharmaceutical formulation comprising a plurality of lipoprotein compound delivery particles of claim 44.

81. (New) The pharmaceutical formulation of claim 80, consisting essentially of said particles in a size of 2 to 20 nanometers in diameter.

82. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 5 to 40 nanometers in diameter.

83. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 10 to 60 nanometers in diameter.

84. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 15 to 100 nanometers in diameter.

85. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 25 to 200 nanometers in diameter.

86. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 50 to 1,000 nanometers in diameter.

87. (New) The pharmaceutical formulation of claim 80, consisting essentially of particles in a size of 250 to 5,000 nanometers in diameter.

88. (New) The pharmaceutical formulation of claim 80, in a pharmaceutically acceptable carrier.

89. (New) The pharmaceutical formulation of claim 88, wherein said carrier is an aqueous carrier.

90. (New) The pharmaceutical formulation of claim 80, in a sterile lyophilized form.

91. (New) A method of delivering a compound to a subject in need thereof, comprising administering a lipoprotein compound delivery particle of claim 44 to said subject in an amount effective to deliver said compound to said subject.

92. (New) The method according to claim 91, wherein said administering step is selected from the group consisting of parenteral injection, intraveneous injection, and topical administration.